COVID-19 Antibodies Linked to MERS-CoV Cross-Reactivity
Severe COVID-19 cases may trigger immune responses that react to MERS-CoV, potentially complicating diagnostic tests.
Updated on Oct. 13, 2026 in Diseases — General
Live Poll
Do you trust that new medical testing methods are generally making healthcare more accurate?
Researchers in the Netherlands discovered that some individuals with severe COVID-19 develop antibodies that bind to MERS-CoV. This cross-reactivity could impact the accuracy of diagnostic testing for MERS-CoV, as the body's response to SARS-CoV-2 overlaps with other coronaviruses.
Why it matters
Understanding this cross-reactivity is essential for clinicians to ensure diagnostic accuracy when testing for MERS-CoV. Because severe infection can trigger broad antibody responses, false-positive results in diagnostic screens may occur if testing is not properly calibrated to distinguish between different coronavirus strains.
In a study of individuals in the Netherlands, researchers measured antibody binding and neutralization capacity in severe COVID-19 patients. Findings showed median MERS-CoV S2 binding at 67.0 IU/mL, while 11 patients demonstrated MERS-CoV neutralizing antibody titers ranging from 26 to 694.
The players
Euroimmun
A manufacturer that produces diagnostic tests, including the commercial MERS-CoV S1 ELISA mentioned in the study.
The details
The cross-reactivity occurs because severe COVID-19 infection stimulates an immune response to conserved epitopes found on the S2 subunit of coronavirus spike proteins. While SARS-CoV-2 antibodies bind to these conserved sites, they also occasionally neutralize MERS-CoV. Testing methods that rely solely on full spike proteins may show binding, but the study notes that S1-based tests, such as standard commercial MERS-CoV S1 ELISAs, remain below the threshold for positivity.
Timeline
October 13, 2026: Findings were published regarding SARS-CoV-2 and MERS-CoV antibody interactions.
Health Landscape
This research contributes to the ongoing refinement of diagnostic specificity protocols for MERS-CoV and SARS-CoV-2 by mapping immune cross-reactivity. It highlights how the body's response to one coronavirus can inadvertently influence testing accuracy for another, guiding future diagnostic development.
If you have a history of severe COVID-19 and require testing for other respiratory illnesses, discuss your clinical background with your doctor to ensure accurate results. Be aware that the body's immune system can produce overlapping markers, making specialized testing sometimes necessary for clarity.
The takeaway
Severe COVID-19 infection may lead to detectable, cross-reactive antibodies that complicate the interpretation of MERS-CoV tests. Patients with a history of severe respiratory illness should disclose this to their physician to help provide context for diagnostic results.
Further reading
For more information on diagnostic accuracy and viral infections, visit the Diseases — General section.
More information
For more information on diagnostic testing technologies, visit the commercial MERS-CoV S1 ELISA provider website.
Source note: This article includes information reported by Cdc.
Live Poll
Do you trust that new medical testing methods are generally making healthcare more accurate?
